QQ客服 官方微博 反馈留言

	A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab
	Xu, Binghe; Ma, Fei; Ouyang, Quchang; Li, Wei; Jiang, Zefei; Tong, Zhongsheng; Liu, Yunjiang; Li, Huiping; Yu, Shiying; Feng, Jifeng
刊名	CANCER RESEARCH
	2018
卷号	78期号:4
ISSN号	0008-5472
URL标识	查看原文
语种	英语
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/3535411
专题	吉林大学白求恩第一医院
推荐引用方式 GB/T 7714	Xu, Binghe,Ma, Fei,Ouyang, Quchang,et al. A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab[J]. CANCER RESEARCH,2018,78(4).
APA	Xu, Binghe.,Ma, Fei.,Ouyang, Quchang.,Li, Wei.,Jiang, Zefei.,...&Zou, Jianjun.(2018).A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab.CANCER RESEARCH,78(4).
MLA	Xu, Binghe,et al."A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab".CANCER RESEARCH 78.4(2018).

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。